Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

被引：0
|
作者：
Junshik Hong
Sae-Won Han
Hye Seon Ham
Tae-Yong Kim
In Sil Choi
Byung-Su Kim
Do-Youn Oh
Seock-Ah Im
Gyeong Hoon Kang
Yung-Jue Bang
Tae-You Kim
机构：
[1] Seoul National University Hospital,Department of Internal Medicine
[2] Seoul National University College of Medicine,Cancer Research Institute
[3] Seoul Municipal Boramae Hospital,Department of Internal Medicine
[4] Seoul National University College of Medicine,Department of Pathology
[5] Graduate School of Convergence Science and Technology,Department of Molecular Medicine & Biopharmaceutical Sciences
[6] Seoul National University,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Colorectal cancer; Oxaliplatin; S-1; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1323 / 1331
页数：8
相关论文
共 50 条
  • [21] A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer
    Lee, Jeeyun
    Shin, Sang Joon
    Chung, Ik Joo
    Kim, Tae Won
    Chun, Hoo-Geun
    Shin, Dong Bok
    Kim, Yeul Hong
    Song, Hong Suk
    Han, Sae-Won
    Kim, Jong Gwang
    Kim, Sun Young
    Choi, Young Jin
    Chung, Hyun Cheol
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 561 - 568
  • [22] Phase I study of biweekly docetaxel and S-1 combination chemotherapy for advanced gastric cancer
    Kunisaki, Chikara
    Takahashi, Masazumi
    Nagahori, Yutaka
    Makino, Hirochika
    Takagawa, Ryo
    Sato, Tsutomu
    Oshima, Takashi
    Fujii, Shoichi
    Kosaka, Takashi
    Ono, Hidetaka A.
    Akiyama, Hirotoshi
    Shimada, Hiroshi
    ANTICANCER RESEARCH, 2008, 28 (4C) : 2473 - 2478
  • [23] Phase II study of S-1 plus irinotecan and oxaliplatin for refractory, heavily treated metastatic colorectal cancer
    Kim, S. Y.
    Hong, Y. S.
    Han, H. S.
    Lim, S. B.
    Choi, H. S.
    Jeong, S. Y.
    Jeong, J. Y.
    Hong, C. W.
    Sohn, D. K.
    Jung, K. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
    Wang, Zhi-Qiang
    Zhang, Dong-Sheng
    Xu, Nong
    Luo, De-Yun
    Deng, Yan-Hong
    Wang, Feng-Hua
    Luo, Hui-Yan
    Qiu, Miao-Zhen
    Li, Yu-Hong
    Xu, Rui-Hua
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [25] A phase II study for triplet combination of oxaliplatin, irinotecan, and S-1 in patients with metastatic or recurrent gastric cancer
    Han, B.
    Park, S. R.
    Kim, H. S.
    Ryu, M-H.
    Kim, J-S.
    Rho, S-Y.
    Kang, B. W.
    Lee, K. H.
    Rha, S. Y.
    Kang, W. K.
    Kang, Y-K.
    Zang, D. Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
  • [27] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [28] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [30] Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer
    Sook Ryun Park
    Yong Sang Hong
    Hyeong-Seok Lim
    Moon-Woo Seong
    Sun-Young Kong
    Sun Young Kim
    Young-Iee Park
    Kyung Hae Jung
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 953 - 964
12345